Lupin inches up as its alliance partner gets USFDA`s final approval for Rocuronium Bromide Injection
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Lupin is currently trading at Rs. 648.10, up by 1.90 points or 0.29% from its previous closing of Rs. 646.20 on the BSE.
The scrip opened at Rs. 657.00 and has touched a high and low of Rs. 657.00 and Rs. 646.80 respectively. So far 1627 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 798.90 on 05-Apr-2022 and a 52 week low of Rs. 583.05 on 25-May-2022.
Last one week high and low of the scrip stood at Rs. 668.80 and Rs. 641.00 respectively. The current market cap of the company is Rs. 29400.89 crore.
The promoters holding in the company stood at 47.10%, while Institutions and Non-Institutions held 43.36% and 9.53% respectively.
Lupin’s alliance partner Caplin Steriles (Caplin) has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated new Drug Application (ANDA) Rocuronium Bromide Injection, 10mg/mL in 5 mL and 10 mL Multi-Dose Vials, to market a generic version of Zemuron Bromide Injection, 50 mg/5 mL and 100 mg/10 mL of Organon USA Inc.
Rocuronium Bromide Injection (RLD: Zemuron) had an annual sale of around $53 million in the U.S. (IQVIA MAT December 2022).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
